HK Stock Market Move | NEXTEER (01316) rises by over 4% again, L3 autonomous driving system gets approval ticket, Tesla industry chain continues to receive positive news recently.
Neptune (01316) rose more than 4% again, as of the time of writing, up 4.04% to HK$7.98, with a turnover of HK$337 million.
NEXTEER (01316) rose by more than 4%, rising by 4.04% to HK$7.98 as of the time of publication, with a turnover of HK$337 million.
On the news front, recently, the "Automobile Industry Stabilization and Growth Plan (2025-2026)" was officially issued, proposing to promote the entry and on-road test of intelligent connected vehicles, and conditionally approve the production access of L3 level vehicle models. Guoce International previously pointed out that with the popularization of L3 and above autonomous driving, the demand for steer-by-wire will increase with the rapid penetration of advanced autonomous driving. As a leading tier1 manufacturer, NEXTEER has a strong first-mover advantage and is the core target for steer-by-wire.
In addition, there have been continuous positive developments in the Tesla supply chain recently. Tesla CEO Musk recently stated that he plans to conduct a technical evaluation of the AI5 chip design on Saturday and will hold a meeting next week on artificial intelligence/autonomous driving systems, Optimus Siasun Robot&Automation, and vehicle production. Guoce International previously stated that NEXTEER is a global leader in steering, and is a scarce target in the autonomous driving and Tesla supply chain.
Related Articles

MENGNIU DAIRY (02319) spent HK$3.0429 million on repurchasing 200,000 shares on September 18th.

China International Marine Containers (02039) spent 9.8927 million Hong Kong dollars on repurchasing 1.2472 million shares on September 18th.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-1139 injection approved for clinical trials
MENGNIU DAIRY (02319) spent HK$3.0429 million on repurchasing 200,000 shares on September 18th.

China International Marine Containers (02039) spent 9.8927 million Hong Kong dollars on repurchasing 1.2472 million shares on September 18th.

Jiangsu Hengrui Pharmaceuticals (01276): SHR-1139 injection approved for clinical trials
